Prognosis of solitary bone plasmacytoma of the extremities
A SEER-based study
Renbo Zhao, MDª, Zhaoxin Chen, MDª, Sujun Zhao, MDª, Yali Cheng, MDª,* Xiaobo Zhu, MDª

Abstract
Due to the rarity of solitary bone plasmacytoma (SBP), few studies reported the prognosis and survival predictors of SBP, especially for patients with extremity SBP.

A total of 552 patients with extremity SBP were identified from the Surveillance Epidemiology and Ends Results (SEER) database between 1973 and 2016. In order to obtain independent predictors of survival, we performed both univariate and multivariate analysis via Cox proportional hazards model. Additionally, we used the Kaplan-Meier method to construct survival curves.

The mean and median age at diagnosis of all patients were 64 and 65 years, respectively. The ratio of male versus women was 3.1:1. Overall survival for this special population was 51.2% and 34.9% at 5 and 10 years, respectively. Cancer-specific survival (CSS) for this special population was 63.5% and 47.5% at 5 and 10 years, respectively. Age at diagnosis and radiotherapy treatment were found to be significant independent predictors of both overall survival and CSS. Additionally, multivariate analysis showed that year of diagnosis and marital status were significantly correlated with CSS.

This is the first study to identify prognostic factors of extremity SBP by using the SEER database. Our findings highlight that radiotherapy is the mainstream treatment for extremity SBP. Additionally, age, year of diagnosis, and marital status were significant independent predictors of survival. Knowledge of these survival predictors may help clinicians provide appropriate management for extremity SBP patients.

Abbreviations: CSS = cancer-specific survival, MM = multiple myeloma, OS = overall survival, SBP = solitary bone plasmacytoma, SEER = Surveillance, Epidemiology, and End Results, SP = solitary plasmacytoma.

Keywords: clinical features, extremity, prognosis, solitary bone plasmacytoma

1. Introduction
Solitary plasmacytoma (SP) is a monoclonal gamma globulin disease with unknown causes, which is characterized with locally proliferating plasma cell tumors and without systemic diseases.[1] To our knowledge, few studies have reported prognosis of solitary bone plasmacytoma of the extremities: A SEER-based study. Medicine 2021;100:26(e26568).

According to the site of involvement, SP can be divided into 2 types: solitary bone plasmacytoma (SBP) and solitary extra-medullary plasmacytoma (SEP). SBP accounts for about 70% of SP, and most commonly occurs in the axial skeleton.[2–4] The median age at diagnosis ranges from 55 to 60 years with male predominance.[5] Patients with SBP have a worse prognosis than SEP cases.[6] Additionally, patients with extremity SBP have a better prognosis than spinal SBP cases.[7]

Although there are many advanced treatment methods for SBP, radiotherapy remains the primary therapy.[8] Surgery is usually performed to treat SBP or prevent its complications.[9] However, the role of surgery in increasing survival remains unknown. Moreover, chemotherapy for treatment of SP is still controversial.[10] To our knowledge, few studies have reported prognosis and treatment methods of patients with extremity SBP due to its rarity. Therefore, this large-scale study is aimed to reveal the clinical features and explore the prognostic predictors among patients with extremity SBP.

2. Materials and methods
2.1. Patient population
We identified SBP cases by using the specific codes (9731/3) of the International Classification of Diseases for Oncology, 3rd edition from the publicly available Surveillance, Epidemiology, and End Results (SEER) database. The present study was conducted according to standard rules and approved by the Institutional Review Board of Taizhou Tumor Hospital.

Received: 27 January 2021 / Received in final form: 2 April 2021 / Accepted: 10 June 2021
http://dx.doi.org/10.1097/MD.0000000000026568

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Editor: Rahul Kumar Jangid.
RZ and ZC contributed equally to this article.
The authors report no conflicts of interest.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

ª Department of Orthopedics, Taizhou Tumor Hospital, Wenling, Zhejiang, China,
ª Department of Orthopedics, Qingtian People’s Hospital, Lishui, Zhejiang, China,
ª Department of Endocrinology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China,
ª Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
* Correspondence: Yali Cheng, No.1 Tongyang Road, Tongyu Street, Luqiao District, Taizhou, Zhejiang 318025, China (e-mail: chengyl@enzemed.com).
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Zhao R, Chen Z, Zhao S, Cheng Y, Zhu X. Prognosis of solitary bone plasmacytoma of the extremities: A SEER-based study. Medicine 2021;100:26(e26568).

Received: 27 January 2021 / Received in final form: 2 April 2021 / Accepted: 10 June 2021
http://dx.doi.org/10.1097/MD.0000000000026568
cases located in the extremity. All cases were confirmed by histopathology. Patients with unknown variables were excluded. We extracted patients’ data from the SEER database, including race, age at diagnosis, sex, year of diagnosis, marital status at diagnosis, surgery, radiotherapy, chemotherapy, vital status, death cause, and survival month. Cause-specific survival (CSS) was calculated as the duration from diagnosis to death due specifically to SBP.[10,11]

2.2. Statistical analysis

We used the IBM SPSS Statistics 22 software to perform statistical analyses. Both univariate and multivariate analyses were performed to obtain independent predictors of overall survival (OS) and CSS via the Cox proportional hazards model. Only variables with \( P < .05 \) from univariate Cox analysis were subsequently integrated into the multivariable analysis to confirm the independent predictors of survival. Survival curves were constructed by using the Kaplan-Meier method. A 2-tailed \( P < .05 \) was considered as statistically significant.

3. Results

3.1. Baseline information

The sociodemographic and clinical characteristics of 552 patients with extremity SBP were shown in Table 1. White people accounted for 81.3%. The mean and median age at diagnosis of all cases were 64 and 65 years, respectively. More than half of patients (60.9%) were aged >60 years. The ratio of male versus women was 1:3:1. Regarding the year of diagnosis, patients diagnosed before 2000 were 12.7%, patients diagnosed between 2000 to 2009 were 45.1%, and patients diagnosed after 2010 were 42.2%. Over half of the patients (62.9%) were married. Treatments included local radiotherapy (76.8%), local surgery (26.1%), and systemic chemotherapy (21.7%). OS for this special population was 51.2% and 34.9% at 5 and 10 years, respectively. CSS for this special population was 63.5% and 47.5% at 5 and 10 years, respectively.

3.2. Univariate survival analysis

Table 2 showed the results of univariate cox regression analysis of survival in detail. There were significant differences depending on age at diagnosis, sex, marital status at diagnosis, and radiotherapy in OS. Significant differences in CSS were found in terms of race, age at diagnosis, sex, year of diagnosis, marital status at diagnosis, and radiotherapy. Survival was worse for patients with age >60 compared to those with age \( \leq 60 \) (Figure 1A and 2A). Patients diagnosed after 2010 experienced better CSS than others (Fig. 2B). Married patients exhibited a better CSS than other patients (Fig. 2C). Patients who did not receive radiotherapy had worse OS and CSS than those who received radiotherapy (Fig. 1B and 2D). Additionally, we observed no significant difference in OS and CSS in terms of chemotherapy or surgery.

3.3. Multivariate survival analysis

Based on the results of multivariate cox regression analysis (Table 3), age \( < 60 \) years and radiotherapy performed were significantly associated with a better OS and CSS. Sex was not an independent predictor of either OS or CSS. Race had no effect on CSS. Additionally, year of diagnosis and marital status at diagnosis were significantly correlated with CSS.

4. Discussion

To date, there are no systematic clinical studies specifically analyzing patients with extremity SBP. Moreover, little is known about how to appropriately treat patients with extremity SBP and improve their prognosis. In this study, we first retrospectively analyzed the clinical characteristics and treatment methods of extremity SBP based on a large cohort of patients. Our study demonstrated that age at diagnosis and radiotherapy were significant independent predictors of both OS and CSS. Additionally, multivariate analysis showed that year of diagnosis and marital status at diagnosis were significantly correlated with CSS.

The median age at diagnosis of this special population was 65 years, which was in agreement with previous studies.[4,9,12] Multivariate analysis indicated that age \( \leq 60 \) significantly predicted an improved OS and CSS among extremity SBP. Other studies on SP also revealed this finding.[12,13] Wang et al[12] reported that older age was a negative independent predictor of OS among patients with spinal SBP. Furthermore, age \( > 60 \) years was associated with progression of plasmacytoma.[14] Sex was

| Table 1 Clinical characteristics of 552 patients with extremity SBP. |
|-------------------------|-----------------|
| Variable                | Value           |
| Race                    |                 |
| White                   | 449 (81.3%)     |
| Black                   | 78 (14.1%)      |
| Others                  | 25 (4.5%)       |
| Age, y                  |                 |
| \( \leq 60 \)            | 216 (39.1%)     |
| \( > 60 \)              | 336 (60.9%)     |
| Sex                     |                 |
| Female                  | 238 (43.1%)     |
| Male                    | 314 (56.9%)     |
| Year of diagnosis       |                 |
| \(< 2000 \)             | 70 (12.7%)      |
| 2000–2009               | 249 (45.1%)     |
| \( \geq 2010 \)          | 233 (42.2%)     |
| Marital status at diagnosis |          |
| Married                 | 347 (62.9%)     |
| Single                  | 65 (11.8%)      |
| Other status            | 140 (25.4%)     |
| Surgery                 |                 |
| Yes                     | 144 (26.1%)     |
| No                      | 408 (73.9%)     |
| Radiotherapy            |                 |
| Yes                     | 424 (76.8%)     |
| No                      | 128 (23.2%)     |
| Chemotherapy            |                 |
| Yes                     | 120 (21.7%)     |
| No                      | 432 (78.3%)     |
| Dead                    |                 |
| Yes                     | 252 (45.7%)     |
| No                      | 300 (54.3%)     |
| 5-y OS rate             |                 |
|                         | 51.2%           |
| 5-y CSS rate            |                 |
|                         | 63.5%           |
| 10-y OS rate            |                 |
|                         | 34.9%           |
| 10-y CSS rate           |                 |
|                         | 47.5%           |

CSS = cancer-specific survival, OS = overall survival, SBP = solitary bone plasmacytoma.
not an independent predictor of OS or CSS. Additionally, predilection of males to females (1.3:1) is not obvious. On multivariate analysis, we noted that marital status at diagnosis was significantly related to CSS. Married patients experienced favorable survival than single or other patients. Other types mainly include divorced, separated, widowed patients. Some studies also reported a survival benefit among married patients with malignant bone tumors.\(^\text{[15-17]}\) Thus,

| Variable                  | Hazard ratio (95% CI) | P      | Hazard ratio (95% CI) | P      |
|---------------------------|-----------------------|--------|-----------------------|--------|
| Race                      |                       |        |                       |        |
| White                     | 1                     |        | 1                     |        |
| Black                     | 0.603 (0.344–1.056)   | .077   | 0.437 (0.192–0.994)   | .048   |
| Others                    | 1.143 (0.606–2.155)   | .679   | 0.916 (0.374–2.244)   | .848   |
| Age, y                    |                       |        |                       |        |
| ≤60                       | 1                     | <.001  | 1                     | <.001  |
| >60                       | 2.680 (2.060–3.488)   |        | 2.701 (1.905–3.829)   | .111   |
| Sex                       |                       |        |                       |        |
| Female                    | 1                     | .783   | 0.667 (0.488–0.913)   | .116   |
| Male                      | 0.794 (0.633–0.997)   |        | 0.427 (0.259–0.704)   | <.001  |
| Year of diagnosis         |                       |        |                       |        |
| <2000                     | 1                     | .119   | 1                     | .001   |
| 2000–2009                 | 0.958 (0.707–1.299)   | .535   | 0.723 (0.483–1.083)   | .804   |
| ≥2010                     | 0.748 (0.519–1.078)   | .001   | 0.427 (0.259–0.704)   | <.001  |
| Marital status at diagnosis|                       |        |                       |        |
| Married                   | 1                     | .612   | 1                     | .621   |
| Single                    | 1.128 (0.770–1.654)   | .535   | 1.072 (0.620–1.853)   | <.001  |
| Other status              | 1.515 (1.179–1.948)   | <.001  | 1.879 (1.337–2.641)   | <.001  |
| Surgery                   |                       |        |                       |        |
| Yes                       | 1                     | .249   | 1                     | .161   |
| No                        | 1.068 (0.828–1.377)   |        | 1.040 (0.766–1.563)   | <.001  |
| Radiotherapy              |                       |        |                       |        |
| Yes                       | 1                     |        | 1                     |        |
| No                        | 1.977 (1.542–2.536)   |        | 2.124 (1.498–3.012)   |        |
| Chemotherapy              |                       |        |                       |        |
| Yes                       | 1                     |        | 1                     |        |
| No                        | 0.852 (0.649–1.119)   |        | 0.770 (0.535–1.109)   |        |

CI = confidence interval, CSS = cancer-specific survival, OS = overall survival, SBP = solitary bone plasmacytoma.

Figure 1. Kaplan-Meier method curves for OS in patients with extremity SPB stratified by (A) age at diagnosis and (B) radiotherapy. CSS = cancer-specific survival, OS = overall survival, SPB = solitary plasmacytoma of bone.
social support and psychological intervention should be actively provided for those vulnerable groups. Multivariate analysis also showed that cases diagnosed after 2010 were significantly associated with better CSS, which may be related to the improvement of modern diagnostic and treatment methods. Knobel et al. reported a 5-year OS rate of 70% among SBP patients, which was higher than ours (51.2%).

Surgery, radiotherapy and chemotherapy are currently used in SP, but radiotherapy is widely recognized as the mainstream treatment. We also found radiotherapy could significantly prolong the OS and CSS of extremity SBP. The role of surgery in survival benefits for SBP remains unknown. This study first revealed that surgery did not improve survival in patients with extremity SBP. Furthermore, compared with radiotherapy alone, surgery combined with radiotherapy did not significantly prolong the life of patients (data not shown). Evidence also showed that high local control rates can be achieved with radiotherapy alone. However, Huang et al. retrospectively analyzed 19 patients with SP of cervical spine and concluded that surgery combined with radiotherapy can control local recurrences and reduce the risk of progression to multiple myeloma (MM). Thus, the advantage of combination therapy including surgical resection remains to be elucidated. Chemotherapy may slow the progressing to MM but may not decrease the survival. Similarly, we found chemotherapy did not have a significant influence on survival.

Although this is the largest study of extremity SBP to date, there are some shortcomings. This is a retrospective observational study with possible bias. The database does not include the records of process of chemotherapy and radiotherapy. Additionally, data of progression to MM and tumor stage are lacking. But

Figure 2. Kaplan-Meier curves for CSS in patients with extremity SBP stratified by (A) age at diagnosis, (B) year of diagnosis, (C) marital status at diagnosis, and (D) radiotherapy. CSS = cancer-specific survival, OS = overall survival, SPB = solitary plasmacytoma of bone.
this study does offer a great opportunity to explore rare tumors like extremity SBP.

5. Conclusions

This is the first population-based SEER analysis of survival in patients with extremity SBP. Radiotherapy and age were found to be significant independent predictors among patients with extremity SBP. Patients with radiotherapy and age \( \geq 60 \), had a relatively better prognosis. Although no evidence showed that surgery or chemotherapy could prolong the survival of extremity SBP, further researches are needed to confirm this finding. To conclude, radiotherapy is the mainstream treatment for extremity SBP. Knowledge of these survival predictors may help clinicians provide appropriate management for extremity SBP patients.

Acknowledgments

The authors thank the contribution of the SEER database.

Author contributions

Conceptualization: Yali Cheng, Xiaobo Zhu.
Data curation: Renbo Zhao.
Formal analysis: Renbo Zhao, Zhaoxin Chen.
Investigation: Renbo Zhao, Zhaoxin Chen.
Methodology: Renbo Zhao, Zhaoxin Chen, Sujun Zhao.
Project administration: Renbo Zhao, Sujun Zhao, Yali Cheng, Xiaobo Zhu.
Software: Zhaoxin Chen, Sujun Zhao.
Supervision: Yali Cheng, Xiaobo Zhu.
Validation: Zhaoxin Chen.
Writing – original draft: Renbo Zhao.

Writing – review & editing: Renbo Zhao, Yali Cheng, Xiaobo Zhu.

References

[1] Grammatico S, Scalfuzi E, Petrucci MT. Solitary plasmacytoma. Mediterr J Hematol Infect Dis 2017;9:e2017052–2017052.
[2] Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004;124:717–26.
[3] Caers J, Paiwa B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma; updated recommendations from a European Expert Panel. J Hematol Oncol 2018;11:10–10.
[4] Thumallapally N, Meshref A, Mousa M, et al. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 2017;17:13–13.
[5] Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 2009;144:86–94.
[6] Finsinger P, Grammatico S, Chisini M, et al. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol 2016;172:534–60.
[7] Dimopoulos MA, Mouloupolou LA, Maniatis A, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037–44.
[8] Pham A, Mahindra A. Solitary plasmacytoma: a review of diagnosis and management. Curr Hematol Malig Rep 2019;14:463–9.
[9] Durr HR, Kuhne JH, Hagena FW, et al. Surgical treatment for myeloma of the bone. A retrospective analysis of 22 cases. Arch Orthop Trauma Surg 1997;116:463–9.
[10] Wang Z, Wu B, Zhou Y, et al. Predictors of the survival of primary and secondary older osteosarcoma patients. J Cancer 2019;10:4614–22.
[11] Wang Z, Cheng Y, Chen S, et al. Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation. Annals of translational medicine 2020;8:197.
[12] Wang Y, Li H, Liu C, et al. Solitary plasmacytoma of bone of the spine: results from Surveillance, Epidemiology, and End Results (SEER) Registry. Spine (Phila Pa 1976) 2019;44:E117–25.
[13] Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 2006;6:118–18.

[14] Jawad MU, Scully SP. Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2009;2:41–141.

[15] Qiu S, Tao L, Zhu Y. Marital status and survival in osteosarcoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Med Sci Monit 2019;25:8190–203.

[16] Gao Z, Ren F, Song H, et al. Marital status and survival of patients with chondrosarcoma: a population-based analysis. Med Sci Monit 2018;24:6638–48.

[17] Jacobs AJ, Michels R, Stein J, et al. Socioeconomic and demographic factors contributing to outcomes in patients with primary lymphoma of bone. J Bone Oncol 2014;4:32–6.

[18] Long S, Li M, Ou S, et al. The effect of marital status on glioma patient survival: analysis of 617 cases: a SEER-based study. Medicine (Baltimore) 2018;97:e13900–13900.

[19] Huang W, Cao D, Ma J, et al. Solitary plasmacytoma of cervical spine: treatment and prognosis in patients with neurological lesions and spinal instability. Spine (Phila Pa 1976) 2010;35:E278–84.

[20] Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 1990;17:293–303.